Drug Trial Radar · NCT05518045
A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
392
Planned (sponsor's estimate)
Start
Aug 26, 2022
Primary completion
Oct 31, 2026
Study completion Oct 31, 2026
Sponsor
- Lead sponsor
- LaNova Medicines LimitedIndustry
- Sponsor type
- Industry
- First posted
- Aug 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase I/II, Open-Label, Dose-Escalation and Dose-Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Efficacy of LM-108, an Anti-CCR8 Monoclonal Antibody, as Monotherapy or in Combination with Antitumor Therapies in Patients with Advanced Solid Tumors
Conditions
- Advanced Solid Tumor
Interventions
LM-108Drug
Administered intravenously
ToripalimabDrug
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I Dose Escalation:Incidence of adverse events (AEs)Time frame: 152 Weeks
- Phase I Dose Escalation:Incidence of dose-limiting toxicity (DLT)Time frame: 152 Weeks
- Phase I Dose Escalation:Incidence of serious adverse event (SAE)Time frame: 152 Weeks
- Phase I Dose Escalation:Incidence of clinical significant in laboratory examinations, including hematology, urinalysis, blood biochemistry, coagulation tests and thyroid function.Time frame: 152 Weeks
- Phase II Dose Expansion Cohort:Objective Response Rate (ORR) Evaluated by Researchers Based on RECIST v1.1Time frame: 152 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.